Response of systemic onset juvenile rheumatoid arthritis to etanercept: is the glass half full or half empty?
Explore the source record for details and available documents.
Antirheumatic Agents↗
Biomedical subjects
B Anne Eberhard
Publications and source records attributed to B Anne Eberhard.
Infliximab as a novel therapy for refractory Kawasaki disease.
Kawasaki disease (KD) is a multisystem vasculitis of unknown etiology, with coronary artery aneurysms occurring in 25% of untreated cases. With conventional treatment of intravenous immunoglobulin (i.v.IG) and high dose aspirin (ASA) only 4% of patients develop coronary artery aneurysms. Children who are unresponsive present a challenge. Tumor necrosis factor-alpha levels peak during the acute and subacute phase of KD, especially in children who develop coronary artery aneurysms. We describe a 3-year-old male with KD and giant coronary artery aneurysms, unresponsive to multiple doses of i.v.IG and methylprednisolone, who was treated with infliximab. After the first dose he defervesced and his laboratory measures improved.
Antibodies, Monoclonal↗
Panniculitis and lipodystrophy.
Panniculitis and lipodystrophy are rare disorders of subcutaneous tissue. Recently the incidence of lipodystrophy has been increasing secondary to its appearance in patients with HIV. In this population, the lipodystrophy appears to be a direct consequence of drug therapy. A review of the available literature regarding pathogenesis and treatment options is discussed. The diagnosis of panniculitis has been hampered by problems. The recent literature has concentrated on ways of improving pathologic diagnostic yields, and new aids in diagnosis are presented.
Adipose Tissue↗
Coexistent sickle cell disease and juvenile rheumatoid arthritis: 2 cases with delayed diagnosis and severe destructive arthropathy.
Explore the source record for details and available documents.
Adolescent↗